创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

李子艳, 王春丽, 黄瑶庆, 高柳滨. 全球糖尿病药物市场概览[J]. 药学进展, 2021, 45(10): 793-800.
引用本文: 李子艳, 王春丽, 黄瑶庆, 高柳滨. 全球糖尿病药物市场概览[J]. 药学进展, 2021, 45(10): 793-800.
LI Ziyan, WANG Chunli, HUANG Yaoqing, GAO Liubin. Report on Global Sales of Antidiabetic Drugs[J]. Progress in Pharmaceutical Sciences, 2021, 45(10): 793-800.
Citation: LI Ziyan, WANG Chunli, HUANG Yaoqing, GAO Liubin. Report on Global Sales of Antidiabetic Drugs[J]. Progress in Pharmaceutical Sciences, 2021, 45(10): 793-800.

全球糖尿病药物市场概览

Report on Global Sales of Antidiabetic Drugs

  • 摘要: 当前,糖尿病药物市场已经成为仅次于肿瘤用药的第二大药品市场。在全球市场上,糖尿病药物种类繁多,除了占据主导地位的胰岛素和传统的α-葡萄糖苷酶抑制剂、磺酰脲类、双胍类和格列奈类等降糖药之外,胰高血糖素样肽-1(GLP-1)、二肽基肽酶Ⅳ(DPPⅣ)和钠-葡萄糖协同转运蛋白-2(SGLT-2)等新靶点糖尿病药物近年来在临床上也得到了广泛的应用,并成为了市场热点。综述近5年全球及中国糖尿病药物市场概况,重点介绍糖尿病新药GLP-1受体激动剂、DPPⅣ抑制剂、SGLT-2抑制剂等的市场态势,以期为我国糖尿病新药研发布局提供参考。

     

    Abstract: Currently, the antidiabetic drug market has become the second largest drug market only to that of anti-tumor drugs. There are many types of antidiabetic drugs on the market. In addition to the dominant insulin and its analogues and traditional drugs such as α-glucosidase inhibitors, sulfonylureas, biguanides and glinides, new target antidiabetic drugs such as GLP-1 agonists, DPP Ⅳ inhibitors and SGLT-2 inhibitors have also been widely used clinically in recent years and have become a hot spot on the market. This paper summarizes the global sales of antidiabetic drugs in the past 5 years, and highlights the market trend of GLP-1 receptor agonists, DPPⅣinhibitors and SGLT-2 inhibitors, in order to provide reference for antidiabetic drug innovation in China.

     

/

返回文章
返回